Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Neoplasm Metastasis 2 Rheumatoid Arthritis, Systemic Juvenile 1 Periodic Fevers Syndrome 1 Mevalonate Kinase Deficiency 1 Metastatic Pancreatic Ductal Adenocarcinoma 1 Melanoma 1 Cryopyrin-Associated Periodic Syndromes 1 Carcinoma 1 Bronchiolitis Obliterans Syndrome 1 Arthritis, Juvenile 1 Arthralgia 1

Interventions

Ipilimumab 98 pembrolizumab 84 Nivolumab 82 aldesleukin 51 Cyclophosphamide 49 Interleukin-2 38 fludarabine phosphate 31 Vemurafenib 31 Dacarbazine 31 dabrafenib 29 trametinib 28 Temozolomide 26 fludarabine 25 CTLA-4 Antigen 18 Bevacizumab 18 Radiosurgery 15 Paclitaxel 15 Carboplatin 14 encorafenib 13 binimetinib 13 Introns 13 talimogene laherparepvec 12 Radiotherapy 12 Interferon alpha-2 12 spartalizumab 11 cobimetinib 10 atezolizumab 10 sargramostim 9 peginterferon alfa-2b 9 montanide ISA 51 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × canakinumab × Clear all

NCT03484923 2024-06-18

PLATforM

Novartis

Phase 2 Completed

196 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡